Pune, May 23, 2025: Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its consolidated financial results for the quarter and year ended March 31st, 2025.
The quarter saw strong performance across both our Domestic and International businesses. Emcure’s Domestic business grew by 24.8% YoY led by our Women’s Health and Cardio franchises and further aided by our new focus areas of Dermatology and OTC. The International business registered a growth of 15.6% led by a robust 39.3% growth in the Rest of the World segment. Our Canada business continues to perform well with Mantra now fully integrated. In Europe we recently acquired a portfolio of products and secured key regulatory approvals which will aid growth going forward.
Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth. Over the past year we have effectively executed our strategies across both Domestic and International markets. On the Domestic side we have expanded our covered market and built a strong product pipeline of upcoming launches. In the International markets we are seeing approvals for our differentiated product offerings. Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies.”
Revenue break-up:
| Rs Cr | 4Q25 | 4Q24 | YOY% | 3Q25 | QOQ% | FY25 | FY24 | YOY% |
| Revenue from operations | 2,116 | 1,771 | 19.5% | 1,963 | 7.8% | 7,896 | 6,658 | 18.6% |
| Domestic | 929 | 744 | 24.8% | 888 | 4.5% | 3,660 | 3,144 | 16.4% |
| International | 1,187 | 1,027 | 15.6% | 1,075 | 10.5% | 4,236 | 3,514 | 20.5% |
| EM | 481 | 345 | 39.3% | 365 | 31.6% | 1,510 | 1,180 | 27.9% |
| EU | 396 | 389 | 1.7% | 358 | 10.6% | 1,474 | 1,411 | 4.4% |
| CA | 310 | 293 | 6.2% | 352 | -11.5% | 1,252 | 923 | 35.7% |
Contd.
Performance Summary (Consolidated)
| Rs Cr | 4Q25 | 4Q24 | YOY% | 3Q25 | QOQ% | FY25 | FY24 | YOY% |
| Revenue from operations | 2,116 | 1,771 | 19.5% | 1,963 | 7.8% | 7,896 | 6,658 | 18.6% |
| Material Cost | 892 | 671 | 33.0% | 783 | 14.0% | 3,147 | 2,475 | 27.1% |
| Gross Profit | 1,224 | 1,100 | 11.2% | 1,180 | 3.7% | 4,749 | 4,183 | 13.5% |
| Gross Profit Margins | 57.8% | 62.1% | 60.1% | 60.1% | 62.8% | |||
| Employee Costs | 373 | 339 | 10.3% | 367 | 1.8% | 1,446 | 1,292 | 11.9% |
| Other expenses | 461 | 450 | 2.3% | 451 | 2.1% | 1,834 | 1,661 | 10.4% |
| EBITDA | 390 | 311 | 25.2% | 362 | 7.8% | 1,469 | 1,230 | 19.4% |
| EBITDA Margins | 18.4% | 17.6% | 18.4% | 18.6% | 18.5% | |||
| Other Income | 4 | 12 | 4 | 67 | 43 | |||
| Depreciation and Amortisation | 97 | 91 | 97 | 384 | 312 | |||
| Finance Costs inc. Forex | 26 | 65 | 39 | 171 | 224 | |||
| Exceptional Items | 10 | 0 | 0 | 10 | 10 | |||
| Profit Before Tax (PBT) | 261 | 167 | 56.1% | 230 | 13.3% | 971 | 727 | 33.6% |
| Tax | 64 | 46 | 74 | 264 | 199 | |||
| Profit After Tax (PAT) | 197 | 121 | 63.0% | 156 | 26.4% | 707 | 528 | 34.1% |
| PAT Margins | 9.3% | 6.8% | 8.0% | 9.0% | 7.9% |
